PinnyPeptide

Dermorphin vs PNC-27

Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.

Peptide A

Dermorphin

Research

Naturally occurring μ-opioid receptor agonist ~30-40× more potent than morphine — research-only.

Peptide B

PNC-27

Research

Membrane-active anticancer research peptide — selectively lyses cancer cell membranes.

Typical vial

2 mg

Typical dose

Research-only mcg

Half-life

~30-60 minutes

FDA status

Not FDA approved. Not scheduled in the US (research peptide …

Typical vial

5 mg

Typical dose

Research-only mcg

Half-life

Variable

FDA status

Not FDA approved.

Dermorphin effects

  • Potent selective μ-opioid receptor agonism
  • Analgesia 30-40× more potent than morphine
  • Sedation and respiratory depression
  • Euphoria (opioid effect)
  • Tolerance and physical dependence develop rapidly with repeated use

PNC-27 effects

  • Selective cancer cell membrane lysis
  • Activity across broad range of cancer cell types in vitro
  • Mechanism involves cancer-cell HDM-2 surface expression
  • Direct tumoricidal effect (not cytostatic)
  • Sparing of normal cells in preclinical models

Dermorphin side effects

  • Respiratory depression (life-threatening at high doses)
  • Sedation, drowsiness
  • Nausea and vomiting
  • Severe constipation
  • Physical dependence and addiction
  • Overdose risk
  • Hyperalgesia with chronic use
  • Hormonal suppression (testosterone, cortisol)

PNC-27 side effects

  • Essentially uncharacterized in humans
  • Theoretical: off-target membrane effects on stressed normal cells
  • Injection-site reactions
  • Possible inflammatory response from rapid cancer-cell lysis
  • Long-term safety unstudied

Dermorphin dosing ranges

Animal opioid pharmacology research

Per protocol (typically µg/kg) · Per protocol · Per protocol

Human self-experimentation

Not appropriate under any circumstances · — · —

PNC-27 dosing ranges

In vitro / animal cancer research

Variable per protocol · Per study design · Per protocol

Human self-experimentation

Not recommended · — · —

Full Dermorphin guide → Full PNC-27 guide →

Dermorphin vs PNC-27 — common questions

What is the difference between Dermorphin and PNC-27?

Dermorphin: Naturally occurring μ-opioid receptor agonist ~30-40× more potent than morphine — research-only. Typical dose Research-only mcg. PNC-27: Membrane-active anticancer research peptide — selectively lyses cancer cell membranes. Typical dose Research-only mcg. Both fall under the Research category.

Can you stack Dermorphin and PNC-27?

Stacking Dermorphin with PNC-27 is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Which is dosed more frequently, Dermorphin or PNC-27?

Dermorphin is typically dosed: Per protocol for Animal opioid pharmacology research; — for Human self-experimentation. PNC-27 is typically dosed: Per study design for In vitro / animal cancer research; — for Human self-experimentation.

Are Dermorphin and PNC-27 FDA approved?

Dermorphin: Not FDA approved. Not scheduled in the US (research peptide status), but functionally an unregulated opioid. PNC-27: Not FDA approved.

Related peptide comparisons

acth-1-39 vs dermorphinacth-1-39 vs pnc-27

Tracking either of these?

Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.

Get Started Free